FR2834295B1 - Cristaux de glucokinase et leurs methodes de culture - Google Patents

Cristaux de glucokinase et leurs methodes de culture

Info

Publication number
FR2834295B1
FR2834295B1 FR0216171A FR0216171A FR2834295B1 FR 2834295 B1 FR2834295 B1 FR 2834295B1 FR 0216171 A FR0216171 A FR 0216171A FR 0216171 A FR0216171 A FR 0216171A FR 2834295 B1 FR2834295 B1 FR 2834295B1
Authority
FR
France
Prior art keywords
glucokinase
crystals
culture
methods
glucokinase crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0216171A
Other languages
English (en)
Other versions
FR2834295A1 (fr
Inventor
Wendy Lea Corbett
Robert Lewis Crowther
Pete William Dunten
R Ursula Kammlott
Christine Maria Lukacs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of FR2834295A1 publication Critical patent/FR2834295A1/fr
Application granted granted Critical
Publication of FR2834295B1 publication Critical patent/FR2834295B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0216171A 2001-12-19 2002-12-19 Cristaux de glucokinase et leurs methodes de culture Expired - Fee Related FR2834295B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34198801P 2001-12-19 2001-12-19

Publications (2)

Publication Number Publication Date
FR2834295A1 FR2834295A1 (fr) 2003-07-04
FR2834295B1 true FR2834295B1 (fr) 2005-03-04

Family

ID=23339854

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0216171A Expired - Fee Related FR2834295B1 (fr) 2001-12-19 2002-12-19 Cristaux de glucokinase et leurs methodes de culture

Country Status (5)

Country Link
US (2) US6911545B2 (fr)
JP (1) JP3734472B2 (fr)
DE (1) DE10259786A1 (fr)
FR (1) FR2834295B1 (fr)
GB (1) GB2385328B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2003097824A1 (fr) * 2002-05-16 2003-11-27 Banyu Pharmaceutical Co., Ltd. Cristal de la proteine de glucokinase et procede d'elaboration de medicament au moyen dudit cristal
BR0314864A (pt) 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2004072066A1 (fr) * 2003-02-11 2004-08-26 Prosidion Limited Composes d'amide a substitution tri(cyclo), activateurs de la glucokinase
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
AU2005229415B2 (en) * 2004-04-02 2009-05-14 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
US7750020B2 (en) 2004-04-02 2010-07-06 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of Type 2 diabetes
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR20070085371A (ko) 2004-10-16 2007-08-27 아스트라제네카 아베 페녹시 벤즈아미드 화합물의 제조 방법
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
CA2614746C (fr) 2005-07-09 2011-05-10 Astrazeneca Ab Derives d'heteroaryl benzamide utilises en tant qu'activateurs de la glk dans le traitement du diabete
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
JP2009514835A (ja) * 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
EP2049518B1 (fr) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Derives de l'indazole et de l'isoindazole comme agents de l'activation de glucokinase
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
UY30822A1 (es) 2006-12-21 2008-07-31 Astrazeneca Ab Fnueva forma cristalina de 3-{[5-azetidin-1-ylcabonyl)pyrazin-2-yl]oxy}-5-[1-methylethyloxy]-n-1h-pyrazol-3-ylbenzamida, composiciones conteniéndola, procesos de preparacion y aplicaciones
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
MX2009009525A (es) * 2007-03-07 2009-09-16 Kyorin Seiyaku Kk Activador de glucocinasa.
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
PE20091313A1 (es) * 2008-01-15 2009-09-03 Lilly Co Eli (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
US20100311072A1 (en) * 2008-01-28 2010-12-09 Bristol-Myers Squibb Company Fluorescence polarization binding assay for characterizing glucokinase ligands
SI2275414T1 (sl) 2008-04-28 2015-10-30 Kyorin Pharmaceutical Co., Ltd., Ciklopentilakrilamidni derivat
CA2732165A1 (fr) 2008-08-04 2010-02-11 Astrazeneca Ab Agents therapeutiques 414
MY158896A (en) * 2008-12-10 2016-11-30 Univ Putra Malaysia Method for crystallizing geobacillus strain t1 polypeptide
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
AR076221A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
JP2014064048A (ja) * 2011-01-27 2014-04-10 Panasonic Corp ネットワーク制御システム、ネットワーク制御機器、ネットワーク被制御機器及び機器制御方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
SI1169312T1 (en) * 1999-03-29 2005-02-28 F. Hoffmann-La Roche Ag Glucokinase activators
KR100502033B1 (ko) 2000-05-03 2005-07-25 에프. 호프만-라 로슈 아게 알키닐 페닐 헤테로방향족 글루코키나제 활성제
KR100519826B1 (ko) 2000-05-08 2005-10-06 에프. 호프만-라 로슈 아게 파라-아민 치환된 페닐아미드 글루코키나제 활성화제
AU778036B2 (en) 2000-05-08 2004-11-11 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
AU2001251467A1 (en) * 2000-05-17 2001-12-03 Princeton University Methods of making models, methods of using models of murg, compounds that bind, inhibit or stimulate muret proteins, and therapeutic compositions thereof
WO2003080585A1 (fr) 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Derive aminobenzamide

Also Published As

Publication number Publication date
US6911545B2 (en) 2005-06-28
GB2385328B (en) 2005-09-21
US20030219887A1 (en) 2003-11-27
US7534593B2 (en) 2009-05-19
DE10259786A1 (de) 2003-07-17
US20060141599A1 (en) 2006-06-29
FR2834295A1 (fr) 2003-07-04
GB0229456D0 (en) 2003-01-22
GB2385328A (en) 2003-08-20
JP3734472B2 (ja) 2006-01-11
JP2003235551A (ja) 2003-08-26

Similar Documents

Publication Publication Date Title
FR2834295B1 (fr) Cristaux de glucokinase et leurs methodes de culture
EP1412417A4 (fr) Nanocomposites polymeriques et procedes de preparation
EP1490373A4 (fr) Inhibiteurs des nucleoside phosphorylases et nucleosidases
NO20041582L (no) Antistoffinhibitorer av GDF-8 og anvendelse derav
EP1603568A4 (fr) Derives d'isoquinoline et leurs methodes d'utilisation
EP1638977A4 (fr) Salinosporamides et leurs methodes d'utilisation
DE60218695D1 (de) Biosensoren und messverfahren
PL373333A1 (pl) Stosowanie przeciwciał skierowanych przeciw TNFalfa i innego leku
DE60221977D1 (de) Pro-pharmakon von cox-2-inhibitoren
NO20011121D0 (no) FremgangsmÕte for formasjonsbehandling med deformerbare partikler
NO20011964D0 (no) Brönnbehandlingsfluider og fremgangsmåter med anvendelse derav
IL162228A (en) Shaped nanocrystal particles and methods for making the same
NO20022176D0 (no) Absorberende gjenstand og fremgangsmåte for fremstilling av denne
EP1482789A4 (fr) Suspension orale de gout agreable et procede associe
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20011026D0 (no) Matvare og fremgangsmÕte for fremstilling derav
DK1381382T3 (da) Fremgangsmåder og præparater til behandling af öjensygdomme
NO20033506L (no) Parasitticidale preparater og metoder for anvendelse
NO20030843L (no) Anordning og fremgangsmåte for kultivering
EP1633749A4 (fr) Composes de deazaflavine et leurs methodes d'utilisation
IS7128A (is) Hreinsun á zaleploni og kristölluð form þess
EP1455858A4 (fr) Composition de catheter et ses utilisations
DK1572180T3 (da) Anvendelse af alfa-phenylthiocarboxylsyrer med serumglucose-sænkende og serumlipid-sænkende virkning
EP1649758A4 (fr) Capsule masticable et procede de fabrication
NO20023737L (no) Fremgangsmåte og preparater for behandling av en inflammatorisk lidelse

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20110831